person · Reporting owner

Borisy Alexis

Disclosed activity across 10 companies

Tapewire entity: 35925
SEC CIK: 0001319446

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813	Director	August 26, 2021	September 23, 2021
Editas Medicine, Inc.EDIT · Entity 5502	Director	June 15, 2017	June 19, 2017
OPKO HEALTH, INC.OPK · Entity 4891	Director	June 22, 2023	June 23, 2023
Parabilis Medicines, Inc.PBLS · Entity 3933	Director	June 11, 2026	June 15, 2026
Relay Therapeutics, Inc.RLAY · Entity 4044	Director	June 09, 2026	June 10, 2026
Revolution Medicines, Inc.RVMD · Entity 606	Director	June 18, 2026	June 23, 2026
Tango Therapeutics, Inc.TNGX · Entity 1497	Director	June 05, 2025	June 09, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Dianthus Therapeutics, Inc. /DE/

Report date August 26, 2021 · Filed September 23, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,100	Reported balance After 2021-08-26 transaction · row 1 1 source row Row 1 · 2021-08-26 · Other · Acquired 4,100 · Balance 4,100 F1: Pro rata distribution from Third Rock Ventures GP IV, L.P., of which the reporting person is a limited partner.

Filing footnotes · ownership attribution and instrument terms

F1: Pro rata distribution from Third Rock Ventures GP IV, L.P., of which the reporting person is a limited partner.

Editas Medicine, Inc.

Report date June 15, 2017 · Filed June 19, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.63 · Expires 2027-06-14	Direct	11,538	Reported balance After 2017-06-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-06-15 · Grant · Acquired 11,538 · Balance 11,538 F1: This option granted on June 15, 2017 and is scheduled to vest in full on June 15, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: This option granted on June 15, 2017 and is scheduled to vest in full on June 15, 2018.

OPKO HEALTH, INC.

Report date June 22, 2023 · Filed June 23, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2033-06-21	Direct	30,000	Reported balance After 2023-06-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-22 · Grant · Acquired 30,000 · Balance 30,000

Parabilis Medicines, Inc.

Report date June 11, 2026 · Filed June 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	105,414	Reported balance After 2026-06-11 transaction · row 1 1 source row Row 1 · 2026-06-11 · Conversion · Acquired 105,414 · Balance 105,414 F1: Each share of Series F Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Preferred Stock had no expiration date.
Series F Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-11 · Conversion · Acquired 162,221 · Balance 0 F1: Each share of Series F Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Preferred Stock had no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series F Preferred Stock (the "Preferred Stock") was convertible into Common Stock on a 1 to 0.6498 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on June 9, 2026 (the "IPO"). The Preferred Stock had no expiration date.

Relay Therapeutics, Inc.

Report date June 09, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.09 · Expires 2036-06-08	Direct	32,947	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 32,947 · Balance 32,947 F1: This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

Revolution Medicines, Inc.

Report date June 18, 2026 · Filed June 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,340,075	Reported balance After 2026-06-18 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-18 · Grant · Acquired 1,191 · Balance 2,340,075 F1: Includes 1,191 restricted stock units.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $162.99 · Expires 2036-06-18	Direct	3,127	Reported balance After 2026-06-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-18 · Grant · Acquired 3,127 · Balance 3,127 F2: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 1,191 restricted stock units.

F2: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 18, 2026 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date.

Tango Therapeutics, Inc.

Report date June 05, 2025 · Filed June 09, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	17,500	Reported balance After 2025-06-05 transaction · row 1 1 source row Row 1 · 2025-06-05 · Grant · Acquired 6,250 · Balance 17,500 F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2026 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.51 · Expires 2035-06-05	Direct	37,500	Reported balance After 2025-06-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-06-05 · Grant · Acquired 37,500 · Balance 37,500 F2: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2026 and (ii) the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

F2: This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year, with the first vesting date on July 5, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Blueprint Medicines Corp

Report date July 17, 2025 · Filed July 21, 2025

Section 16 reporting ended · disclosed 2025-07-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2025-07-17 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2025-07-17 · Disposition to issuer · Disposed 3,902 · Balance 74,160 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration. Row 2 · 2025-07-17 · Other · Disposed 74,160 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.79	Direct	Reported balance After 2025-07-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-07-17 · Disposition to issuer · Disposed 7,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $96.77	Direct	Reported balance After 2025-07-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-07-17 · Disposition to issuer · Disposed 4,875 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.24	Direct	Reported balance After 2025-07-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-07-17 · Disposition to issuer · Disposed 4,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.13	Direct	Reported balance After 2025-07-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-07-17 · Disposition to issuer · Disposed 4,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.64	Direct	Reported balance After 2025-07-17 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-07-17 · Disposition to issuer · Disposed 5,300 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.66	Direct	Reported balance After 2025-07-17 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-07-17 · Disposition to issuer · Disposed 5,300 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.14	Direct	Reported balance After 2025-07-17 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-07-17 · Disposition to issuer · Disposed 4,570 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

EQRx, Inc.

Report date November 09, 2023 · Filed November 09, 2023

Section 16 reporting ended · disclosed 2023-11-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2023-11-09 transaction · row 1 1 source row Row 1 · 2023-11-09 · Disposition to issuer · Disposed 18,810,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F2: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.68 · Expires 2031-06-06	Direct	Reported balance After 2023-11-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-11-09 · Disposition to issuer · Disposed 2,194,499 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F3: Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time. F4: At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an "In-the-Money Option") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration).
Earn-out SharesSEC Table II · derivative / convertible security · Expires 2024-12-17	Direct	Reported balance After 2023-11-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-11-09 · Disposition to issuer · Disposed 2,892,491 · Balance 0 F5: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021 (the "DeSPAC Merger Agreement"), by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the Reporting Person was allocated the right to acquire an aggregate of 2,892,491 shares of Issuer common stock (the "Earn-out Shares"), (i) 2,024,743 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 867,748 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. F6: Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment pursuant to the terms of the DeSPAC Merger Agreement. F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines. F2: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F7: Each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time and held in escrow subject to the earn-out on the terms and subject to the conditions of the DeSPAC Merger Agreement was converted in the same manner as all other shares of Issuer common stock under the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger dated July 31, 2023 (the "Merger Agreement"), by and among the Issuer, Revolution Medicines, Inc. ("Revolution Medicines"), Equinox Merger Sub, Inc., a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub I"), and Equinox Merger Sub II LLC, a direct, wholly owned subsidiary of Revolution Medicines ("Merger Sub II"), pursuant to which Merger Sub I merged with and into the Issuer effective as of November 9, 2023 (the "Effective Time"), with the Issuer surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines (the "First Merger"), and promptly after the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving such merger as a direct, wholly owned subsidiary of Revolution Medicines.

F2: At the Effective Time, each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive a number of validly issued, fully paid and non-assessable shares of Revolution Medicines common stock equal to 0.1112 (the "Exchange Ratio") and cash in lieu of any fractional shares of Revolution Medicines common stock any former holder of Issuer common stock would otherwise be entitled to receive, without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F3: Pursuant to the Merger Agreement, each Issuer stock option that was outstanding and unexercised became fully vested and exercisable as of immediately prior to the Effective Time.

F4: At the Effective Time, each Issuer stock option that was outstanding immediately prior to the Effective Time and had an exercise price per share less than $2.16 (an "In-the-Money Option") was cancelled and converted automatically into the right to receive a number of shares of Revolution Medicines common stock equal to the quotient of (i) the product of (a) the number of shares of Issuer common stock subject to the In-the-Money Option immediately prior to the Effective Time, multiplied by (b) the excess of $2.16 over the exercise price of such In-the-Money Option, divided by (ii) $19.4690, less the number of shares of Revolution Medicines common stock having a fair market value as of the Effective Time equal to the amount necessary to satisfy the award holder's tax withholding obligations. (All Issuer stock options that did not constitute In-the-Money Options were terminated at the Effective Time for no consideration).

F5: Pursuant to the terms of the Agreement and Plan of Merger dated August 5, 2021 (the "DeSPAC Merger Agreement"), by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc.), the Reporting Person was allocated the right to acquire an aggregate of 2,892,491 shares of Issuer common stock (the "Earn-out Shares"), (i) 2,024,743 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 867,748 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50.

F6: Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment pursuant to the terms of the DeSPAC Merger Agreement.

F7: Each share of Issuer common stock that was issued and outstanding immediately prior to the Effective Time and held in escrow subject to the earn-out on the terms and subject to the conditions of the DeSPAC Merger Agreement was converted in the same manner as all other shares of Issuer common stock under the Merger Agreement.

Foundation Medicine, Inc.

Report date July 31, 2018 · Filed August 02, 2018

Section 16 reporting ended · disclosed 2018-08-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2018-07-31 transaction · row 1 1 source row Row 1 · 2018-07-31 · Other · Disposed 73,173 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche.
stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.21 · Expires 2024-06-18	Direct	0	Reported balance After 2018-07-31 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-07-31 · Other · Disposed 13,385 · Balance 0 F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F3: The amount reported represents the number of vested stock options cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share minus the per share exercise price of the vested stock options, multiplied by (2) the number of shares represented by such vested stock options, without interest and less any required withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company.

F2: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche.

F3: The amount reported represents the number of vested stock options cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share minus the per share exercise price of the vested stock options, multiplied by (2) the number of shares represented by such vested stock options, without interest and less any required withholding taxes.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 27, 2022 Filed May 27, 2022 21:37 UTC	Relay Therapeutics, Inc. RLAY · Entity 4044	GrantStock Option (Right to Buy) · Derivative	41,597	$0.00 Strike: $17.33	$0.00	Disclosure SEC source: 0001209191-22-032676 · doc4.xml · derivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,597 Underlying: Common Stock · 41,597 shares Expires 2032-05-26 F1 · derivative.exercise_date: This option was granted on May 27, 2022 with respect to 41,597 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document
May 09, 2022 Filed May 12, 2022 01:00 UTC	OPKO HEALTH, INC. OPK · Entity 4891	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $2.44	$0.00	Disclosure SEC source: 0001209191-22-028424 · doc4.xml · derivative · entry 2 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-05-08 Read SEC document
May 09, 2022 Filed May 12, 2022 01:00 UTC	OPKO HEALTH, INC. OPK · Entity 4891	GrantCommon Stock	312,612	$0.00	$0.00	Disclosure SEC source: 0001209191-22-028424 · doc4.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,612 F1 · shares: On May 9, 2022, the Issuer awarded the Reporting Person restricted stock in the amount indicated. The restricted stock vests in four equal installments, beginning on May 9, 2023. Read SEC document
May 09, 2022 Filed May 13, 2022 22:19 UTC Amendment	OPKO HEALTH, INC. OPK · Entity 4891	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $2.44	$0.00	Disclosure SEC source: 0001209191-22-028956 · doc4a.xml · derivative · entry 2 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-05-08 Read SEC document
May 09, 2022 Filed May 13, 2022 22:19 UTC Amendment	OPKO HEALTH, INC. OPK · Entity 4891	GrantCommon Stock	312,612	$0.00	$0.00	Disclosure SEC source: 0001209191-22-028956 · doc4a.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,612 F1 · shares: On May 9, 2022, the Issuer awarded the Reporting Person restricted stock in the amount indicated in connection with the merger between the Issuer and ModeX Therapeutics, Inc. ("ModeX"), pursuant to which ModeX became a subsidiary of the Issuer. Read SEC document
December 17, 2021 Filed Dec 21, 2021 06:30 UTC	EQRx, Inc. EQRX · Entity 108311	GrantEarn-out Shares · Derivative	2,877,343	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-049124 · doc4.xml · derivative · entry 3 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,877,343 Underlying: Common Stock · 2,877,343 shares Expires 2024-12-17 F3 · derivative.exercise_price: Upon consummation of the Business Combination, the Reporting Person received the right to acquire 2,877,343 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 2,014,139 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 863,204 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement. F3 · kind: Upon consummation of the Business Combination, the Reporting Person received the right to acquire 2,877,343 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 2,014,139 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 863,204 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement. F3 · price: Upon consummation of the Business Combination, the Reporting Person received the right to acquire 2,877,343 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 2,014,139 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 863,204 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement. F3 · derivative.exercise_date: Upon consummation of the Business Combination, the Reporting Person received the right to acquire 2,877,343 shares of the Issuer's Common Stock (the "Earn-out Shares"), (i) 2,014,139 of which will be released from escrow if the value weighted average price ("VWAP") for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $12.50; and (ii) 863,204 of which will be released from such escrow if the VWAP for at least 20 of any 30 consecutive trading days following December 17, 2022 is at least $16.50. Any Earn-out Shares not eligible to be released on or prior to December 17, 2024 will be forfeited and cancelled, and the maximum number of Earn-out Shares the Reporting Person may be eligible to acquire is subject to adjustment per the terms of the Merger Agreement. Read SEC document
December 17, 2021 Filed Dec 21, 2021 06:30 UTC	EQRx, Inc. EQRX · Entity 108311	GrantStock Option (Right to Buy) · Derivative	2,194,499	$0.00 Strike: $2.68	$0.00	Disclosure SEC source: 0000899243-21-049124 · doc4.xml · derivative · entry 2 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,194,499 Underlying: Common Stock · 2,194,499 shares Expires 2031-06-06 F2 · kind: These options were issued under the Legacy EQRx 2019 Stock Option and Grant Plan (the "2019 Plan") and were assumed in the Business Combination pursuant to the terms of the Merger Agreement and the 2019 Plan and are now exercisable for shares of the Issuer's Common Stock. The shares underlying this option vest and become exercisable in 48 equal monthly installments commencing September 1, 2021, subject to the Reporting Person's continuous service as of each vesting date. F2 · derivative.exercise_date: These options were issued under the Legacy EQRx 2019 Stock Option and Grant Plan (the "2019 Plan") and were assumed in the Business Combination pursuant to the terms of the Merger Agreement and the 2019 Plan and are now exercisable for shares of the Issuer's Common Stock. The shares underlying this option vest and become exercisable in 48 equal monthly installments commencing September 1, 2021, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document
December 17, 2021 Filed Dec 21, 2021 06:30 UTC	EQRx, Inc. EQRX · Entity 108311	GrantCommon Stock	18,810,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-049124 · doc4.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,810,000 F1 · kind: On December 17, 2021, upon consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of Legacy EQRx capital stock was exchanged, pursuant to the Merger Agreement, for shares of the Issuer's Common Stock. F1 · price: On December 17, 2021, upon consummation of the transactions (the "Closing" of the "Business Combination") contemplated by the Agreement and Plan of Merger dated August 5, 2021 (the "Merger Agreement") by and among the Issuer (f/k/a CM Life Sciences III Inc.), Clover III Merger Sub Inc. and EQRx International, Inc. (f/k/a EQRx, Inc., "Legacy EQRx"), each share of Legacy EQRx capital stock was exchanged, pursuant to the Merger Agreement, for shares of the Issuer's Common Stock. Read SEC document
August 26, 2021 Filed Sep 23, 2021 20:47 UTC	Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813	OtherCommon Stock	4,100	$0.00	$0.00	Disclosure SEC source: 0000899243-21-037336 · doc4.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,100 F1 · kind: Pro rata distribution from Third Rock Ventures GP IV, L.P., of which the reporting person is a limited partner. Read SEC document
June 22, 2021 Filed Jun 24, 2021 21:14 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantStock Option (Right to Buy) · Derivative	12,659	$0.00 Strike: $32.93	$0.00	Disclosure SEC source: 0001567619-21-012587 · doc1.xml · derivative · entry 2 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,659 Underlying: Common Stock · 12,659 shares Expires 2031-06-21 F3 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 22, 2021 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document
June 22, 2021 Filed Jun 24, 2021 21:14 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantCommon Stock	3,617	$0.00	$0.00	Disclosure SEC source: 0001567619-21-012587 · doc1.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,718 F1 · balance_after: Includes 3,617 Restricted Stock Units. F2 · balance_after: On September 10, 2020, December 3, 2020, and February 25, 2021, Third Rock Ventures GP III, L.P. distributed 639, 639 and 43,015 shares, respectively, to the Reporting Person through in-kind, pro rata distributions without value. The distributions were exempt Section 16 of the Exchange Act pursuant to Rule 16a-9. Read SEC document
June 02, 2021 Filed Jun 4, 2021 20:15 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	4,500	$0.00 Strike: $87.13	$0.00	Disclosure SEC source: 0001179110-21-006415 · edgar.xml · derivative · entry 2 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2031-06-02 F2 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022. Read SEC document
June 02, 2021 Filed Jun 4, 2021 20:15 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantCommon Stock	2,250	$0.00	$0.00	Disclosure SEC source: 0001179110-21-006415 · edgar.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,718 F1 · kind: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 2, 2022. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
June 01, 2021 Filed Jun 3, 2021 22:27 UTC	Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813	GrantStock Option (Right to Buy) · Derivative	18,188	$0.00 Strike: $12.91	$0.00	Disclosure SEC source: 0000899243-21-021836 · doc4.xml · derivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2031-05-31 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 1, 2022 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document
May 19, 2021 Filed May 21, 2021 23:43 UTC	Relay Therapeutics, Inc. RLAY · Entity 4044	GrantStock Option (Right to Buy) · Derivative	16,000	$0.00 Strike: $30.09	$0.00	Disclosure SEC source: 0001209191-21-035113 · doc4.xml · derivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2031-05-18 F1 · derivative.exercise_date: This option was granted on May 19, 2021 with respect to 16,000 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date. Read SEC document
March 11, 2021 Filed Mar 25, 2021 11:42 UTC	Relay Therapeutics, Inc. RLAY · Entity 4044	OtherCommon Stock	28,538	$0.00	$0.00	Disclosure SEC source: 0001209191-21-021057 · doc4.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,175 F1 · kind: Pro rata distribution from Third Rock Ventures GP III, L.P., of which the reporting person is a limited partner. Read SEC document
February 19, 2021 Filed Feb 20, 2021 01:00 UTC	Relay Therapeutics, Inc. RLAY · Entity 4044	OtherCommon Stock	30,194	$0.00	$0.00	Disclosure SEC source: 0001209191-21-012595 · doc4.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,637 F1 · kind: Pro rata distribution from Third Rock Ventures GP III, L.P., of which the reporting person is a limited partner. Read SEC document
February 05, 2021 Filed Feb 10, 2021 01:00 UTC	Relay Therapeutics, Inc. RLAY · Entity 4044	OtherCommon Stock	70,956	$0.00	$0.00	Disclosure SEC source: 0001209191-21-009057 · doc4.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,443 F1 · kind: Pro rata distribution from Third Rock Ventures GP III, L.P., of which the reporting person is a limited partner. Read SEC document
July 20, 2020 Filed Jul 21, 2020 23:14 UTC	Relay Therapeutics, Inc. RLAY · Entity 4044	ConversionSeries C Convertible Preferred Stock · Derivative	371,027	$0.00	$0.00	Disclosure SEC source: 0000899243-20-019839 · doc4.xml · derivative · entry 2 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 104,487 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series C Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date. F1 · derivative.exercise_date: Each share of Series C Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date. F1 · derivative.expiration_date: Each share of Series C Preferred Stock automatically converted into shares of the Issuer's common stock, par value $0.001 per share on a 1-for-3.55092 basis upon the closing of the Issuer's initial public offering on July 20, 2020 and had no expiration date. Read SEC document
July 20, 2020 Filed Jul 21, 2020 23:14 UTC	Relay Therapeutics, Inc. RLAY · Entity 4044	ConversionCommon Stock	104,487	$0.00	$0.00	Disclosure SEC source: 0000899243-20-019839 · doc4.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 24, 2020 Filed Jun 26, 2020 20:11 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	4,500	$0.00 Strike: $76.24	$0.00	Disclosure SEC source: 0001179110-20-007795 · edgar.xml · derivative · entry 2 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2030-06-24 F2 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021. Read SEC document
June 24, 2020 Filed Jun 26, 2020 20:11 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantCommon Stock	2,250	$0.00	$0.00	Disclosure SEC source: 0001179110-20-007795 · edgar.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,468 F1 · kind: The reported transaction involved the Reporting Person's receipt of a grant of restricted stock units. The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 24, 2021. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
June 19, 2020 Filed Jun 23, 2020 20:20 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionRestricted Stock Units · Derivative	1,312	$0.00	$0.00	Disclosure SEC source: 0001179110-20-007723 · edgar.xml · derivative · entry 2 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,312 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested. F2 · derivative.expiration_date: On June 19, 2019, the reporting person was granted 1,312 restricted stock units. These restricted stock units are fully vested. Read SEC document
June 19, 2020 Filed Jun 23, 2020 20:20 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	1,312	Not disclosed	Not disclosed	Disclosure SEC source: 0001179110-20-007723 · edgar.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,218 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
June 17, 2020 Filed Jun 19, 2020 19:37 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantStock Option (Right to Buy) · Derivative	6,329	$0.00 Strike: $36.57	$0.00	Disclosure SEC source: 0001567619-20-012447 · doc1.xml · derivative · entry 2 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,329 Underlying: Common Stock · 6,329 shares Expires 2030-06-16 F2 · derivative.exercise_date: Shares subject to the Option shall vest in full on the earlier of (i) the first anniversary of June 17, 2020 or (ii) immediately prior to the Annual Meeting following the date of grant subject to the Reporting Person remaining a Service Provider (as defined in the 2020 Plan) through the vesting date. Read SEC document
June 17, 2020 Filed Jun 19, 2020 19:37 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantCommon Stock	1,808	$0.00	$0.00	Disclosure SEC source: 0001567619-20-012447 · doc1.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,808 F1 · balance_after: Includes 1,808 Restricted Stock Units. Read SEC document
June 05, 2020 Filed Jun 9, 2020 20:32 UTC	Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813	GrantStock Option (Right to Buy) · Derivative	18,188	$0.00 Strike: $9.99	$0.00	Disclosure SEC source: 0000899243-20-015808 · doc4.xml · derivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2030-06-04 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document
June 27, 2019 Filed Jul 1, 2019 23:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	10,909	$0.00 Strike: $46.02	$0.00	Disclosure SEC source: 0001179110-19-008262 · edgar.xml · derivative · entry 6 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,909 shares Expires 2027-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on June 21, 2017. This option vested with respect to 100% of the shares underlying the option on June 20, 2018. Read SEC document
June 27, 2019 Filed Jul 1, 2019 23:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionStock Option (Right to Buy) · Derivative	10,909	$0.00 Strike: $19.53	$0.00	Disclosure SEC source: 0001179110-19-008262 · edgar.xml · derivative · entry 5 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,909 shares Expires 2026-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on June 23, 2016. This option vested with respect to 100% of the shares underlying the option on June 20, 2017. Read SEC document
June 27, 2019 Filed Jul 1, 2019 23:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	968	$91.55	$88,620.40	Disclosure SEC source: 0001179110-19-008262 · edgar.xml · nonDerivative · entry 4 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,906 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.45 to $91.68 per share. Read SEC document
June 27, 2019 Filed Jul 1, 2019 23:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	20,850	$92.03	$1,918,825.50	Disclosure SEC source: 0001179110-19-008262 · edgar.xml · nonDerivative · entry 3 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,874 F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.69 to $92.68 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (3) of this Form 4. Read SEC document
June 27, 2019 Filed Jul 1, 2019 23:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	10,909	$46.02	$502,032.18	Disclosure SEC source: 0001179110-19-008262 · edgar.xml · nonDerivative · entry 2 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 27, 2019 Filed Jul 1, 2019 23:23 UTC	Blueprint Medicines Corp BPMC · Entity 77326	Exercise / conversionCommon Stock	10,909	$19.53	$213,052.77	Disclosure SEC source: 0001179110-19-008262 · edgar.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,815 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 7,657 shares received on April 4, 2019 through a distribution of shares in kind by Third Rock Ventures GP II, L.P. to its partners. Read SEC document
June 19, 2019 Filed Jun 20, 2019 20:35 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantRestricted Stock Units · Derivative	1,312	$0.00	$0.00	Disclosure SEC source: 0001179110-19-007980 · edgar.xml · derivative · entry 2 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,312 Underlying: Common Stock · 1,312 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020. F3 · derivative.expiration_date: The restricted stock units vest with respect to 100% of the shares underlying the restricted stock units on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020. Read SEC document
June 19, 2019 Filed Jun 20, 2019 20:35 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	4,875	$0.00 Strike: $96.77	$0.00	Disclosure SEC source: 0001179110-19-007980 · edgar.xml · derivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,875 Underlying: Common Stock · 4,875 shares Expires 2029-06-19 F1 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 19, 2020. Read SEC document
June 07, 2019 Filed Jun 11, 2019 21:00 UTC	Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813	GrantStock Option (Right to Buy) · Derivative	18,188	$0.00 Strike: $13.40	$0.00	Disclosure SEC source: 0000899243-19-016407 · doc4.xml · derivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2029-06-06 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 7, 2020 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document
July 31, 2018 Filed Aug 2, 2018 16:03 UTC	Foundation Medicine, Inc. FMI · Entity 164565	Otherstock option (right to buy) · Derivative	13,385	$0.00 Strike: $24.21	$0.00	Disclosure SEC source: 0001209191-18-044916 · doc4.xml · derivative · entry 2 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,385 shares Expires 2024-06-18 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F3 · shares: The amount reported represents the number of vested stock options cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share minus the per share exercise price of the vested stock options, multiplied by (2) the number of shares represented by such vested stock options, without interest and less any required withholding taxes. Read SEC document
July 31, 2018 Filed Aug 2, 2018 16:03 UTC	Foundation Medicine, Inc. FMI · Entity 164565	OtherCommon Stock	73,173	$137.00	$10,024,701.00	Disclosure SEC source: 0001209191-18-044916 · doc4.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: Foundation Medicine, Inc., a Delaware corporation (the "Company") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the "Merger Agreement"), with Roche Holdings, Inc., a Delaware corporation ("Parent" or "Roche"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the "Tender Offer") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company. F2 · shares: The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche. Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:24 UTC	Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813	ConversionSeries B Preferred Stock · Derivative	0	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-018315 · doc4.xml · derivative · entry 3 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F4 · shares: Prior to the conversion, the Fund held 20,102,478 shares of Series A Preferred Stock and 340,566 shares of Series B Preferred Stock. F2 · price: The Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: The Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: The Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F5 · derivative.underlying_shares: Prior to the conversion, the shares of Common Stock underlying the Series A Preferred Stock and Series B Preferred Stock held by the Fund were 7,779,656 and 131,799, respectively. F3 · ownership.nature: The Reporting Person is a partner of Third Rock Ventures GP IV, L.P., which is the general partner of the Fund. The reporting person disclaims beneficial ownership over the shares held by the Fund, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:24 UTC	Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813	ConversionSeries A Preferred Stock · Derivative	0	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-018315 · doc4.xml · derivative · entry 2 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F4 · shares: Prior to the conversion, the Fund held 20,102,478 shares of Series A Preferred Stock and 340,566 shares of Series B Preferred Stock. F2 · price: The Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: The Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: The Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F5 · derivative.underlying_shares: Prior to the conversion, the shares of Common Stock underlying the Series A Preferred Stock and Series B Preferred Stock held by the Fund were 7,779,656 and 131,799, respectively. F3 · ownership.nature: The Reporting Person is a partner of Third Rock Ventures GP IV, L.P., which is the general partner of the Fund. The reporting person disclaims beneficial ownership over the shares held by the Fund, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Read SEC document
June 25, 2018 Filed Jun 27, 2018 20:24 UTC	Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813	ConversionCommon Stock	0	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-018315 · doc4.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents 7,911,455 shares held by Third Rock Ventures IV, L.P. (the "Fund") received by the Fund upon conversion of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") upon closing of the Issuer's initial public offering on June 25, 2018. F2 · price: The Preferred Stock converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F3 · ownership.nature: The Reporting Person is a partner of Third Rock Ventures GP IV, L.P., which is the general partner of the Fund. The reporting person disclaims beneficial ownership over the shares held by the Fund, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Read SEC document
June 21, 2018 Filed Jun 25, 2018 20:54 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $69.79	$0.00	Disclosure SEC source: 0001179110-18-008997 · edgar.xml · derivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,318 Underlying: Common Stock · 7,500 shares Expires 2028-06-21 F1 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 21, 2019. Read SEC document
May 11, 2018 Filed May 14, 2018 23:38 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	0	$0.00	$0.00	Disclosure SEC source: 0000899243-18-012782 · doc4.xml · nonDerivative · entry 2 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F4 · shares: On May 11, 2018, TRV II sold (i) 71,778 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $78.03 to $78.73, inclusive, at a weighted average price per share of $78.0398. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4). F4 · price: On May 11, 2018, TRV II sold (i) 71,778 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $78.03 to $78.73, inclusive, at a weighted average price per share of $78.0398. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4). F5 · balance_after: After the above transaction, TRV II owned 878,875 shares of Common Stock of the Issuer. F3 · ownership.nature: The reporting person is a partner of Third Rock Ventures GP II, L.P., which is the general partner of the TRV II. The reporting person disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Read SEC document
May 10, 2018 Filed May 14, 2018 23:38 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	0	$0.00	$0.00	Disclosure SEC source: 0000899243-18-012782 · doc4.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · shares: On May 10, 2018, Third Rock Ventures II, L.P. ("TRV II") sold (i) 210,000 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $80.05 to $80.25, inclusive, at a weighted average price per share of $80.0503 and (ii) 200 shares of Common Stock of the Issuer at a price of $81.11 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). F1 · price: On May 10, 2018, Third Rock Ventures II, L.P. ("TRV II") sold (i) 210,000 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $80.05 to $80.25, inclusive, at a weighted average price per share of $80.0503 and (ii) 200 shares of Common Stock of the Issuer at a price of $81.11 per share. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). F2 · balance_after: After the above transaction, TRV II owned 950,653 shares of Common Stock of the Issuer. F3 · ownership.nature: The reporting person is a partner of Third Rock Ventures GP II, L.P., which is the general partner of the TRV II. The reporting person disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Read SEC document
May 09, 2018 Filed May 11, 2018 20:34 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	0	$0.00	$0.00	Disclosure SEC source: 0000899243-18-012543 · doc4.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · shares: On May 9, 2018, Third Rock Ventures II, L.P. ("TRV II") sold (i) 810,000 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $79.05 to $79.42, inclusive, at a weighted average price per share of $79.0502 and (ii) 15,400 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $80.07 to $80.12, inclusive, at a weighted average price per share of $80.0713. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). F1 · price: On May 9, 2018, Third Rock Ventures II, L.P. ("TRV II") sold (i) 810,000 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $79.05 to $79.42, inclusive, at a weighted average price per share of $79.0502 and (ii) 15,400 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $80.07 to $80.12, inclusive, at a weighted average price per share of $80.0713. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). F2 · balance_after: After the above transaction, TRV II owned 1,160,853 shares of Common Stock of the Issuer. F3 · ownership.nature: The reporting person is a partner of Third Rock Ventures GP II, L.P., which is the general partner of the TRV II. The reporting person disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Read SEC document
May 07, 2018 Filed May 8, 2018 20:57 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	0	$0.00	$0.00	Disclosure SEC source: 0000899243-18-011871 · doc4.xml · nonDerivative · entry 2 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F4 · shares: On May 7, 2018, TRV II sold (i) 284,378 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $78.10 to $79.07, inclusive, at a weighted average price per share of $78.5484 and (ii) 33,122 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $79.12 to $79.57, inclusive, at a weighted average price per share of $79.3597. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4). F4 · price: On May 7, 2018, TRV II sold (i) 284,378 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $78.10 to $79.07, inclusive, at a weighted average price per share of $78.5484 and (ii) 33,122 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $79.12 to $79.57, inclusive, at a weighted average price per share of $79.3597. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4). F5 · balance_after: After the above transaction, TRV II owned 1,986,253 shares of Common Stock of the Issuer. F3 · ownership.nature: The reporting person is a partner of Third Rock Ventures GP II, L.P., which is the general partner of the TRV II. The reporting person disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Read SEC document
May 04, 2018 Filed May 8, 2018 20:57 UTC	Blueprint Medicines Corp BPMC · Entity 77326	SaleCommon Stock	0	$0.00	$0.00	Disclosure SEC source: 0000899243-18-011871 · doc4.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · shares: On May 4, 2018, Third Rock Ventures II, L.P. ("TRV II") sold (i) 130,000 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $78.35 to $79.12, inclusive, at a weighted average price per share of $78.9148 and (ii) 20,000 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $79.40 to $79.80, inclusive, at a weighted average price per share of $79.4912. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). F1 · price: On May 4, 2018, Third Rock Ventures II, L.P. ("TRV II") sold (i) 130,000 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $78.35 to $79.12, inclusive, at a weighted average price per share of $78.9148 and (ii) 20,000 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $79.40 to $79.80, inclusive, at a weighted average price per share of $79.4912. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1). F2 · balance_after: After the above transaction, TRV II owned 2,303,753 shares of Common Stock of the Issuer. F3 · ownership.nature: The reporting person is a partner of Third Rock Ventures GP II, L.P., which is the general partner of the TRV II. The reporting person disclaims beneficial ownership over such shares, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares. Read SEC document
June 21, 2017 Filed Jun 23, 2017 20:26 UTC	Blueprint Medicines Corp BPMC · Entity 77326	GrantStock Option (Right to Buy) · Derivative	10,909	$0.00 Strike: $46.02	$0.00	Disclosure SEC source: 0001179110-17-009523 · edgar.xml · derivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,818 Underlying: Common Stock · 10,909 shares Expires 2027-06-21 F1 · derivative.exercise_date: This option vests with respect to 100% of the shares underlying the option on the earlier of (i) the next annual meeting of the Issuer's stockholders and (ii) June 21, 2018. Read SEC document
June 20, 2017 Filed Jun 22, 2017 16:04 UTC	Foundation Medicine, Inc. FMI · Entity 164565	GrantCommon Stock	5,786	$40.05	$231,729.30	Disclosure SEC source: 0001209191-17-041329 · doc4.xml · nonDerivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,173 F1 · shares: Represents restricted stock units granted by the Issuer pursuant to its 2013 Stock Option and Incentive Plan and the Issuer's Non-Employee Director Compensation Policy. The restricted stock units vest on the earlier of June 20, 2018 or the Issuer's next annual meeting of stockholders, subject to the director's continued service on the Board of Directors, or immediately upon the death or disability of the director or upon a change-of-control of the Issuer. Read SEC document
June 15, 2017 Filed Jun 19, 2017 20:04 UTC	Editas Medicine, Inc. EDIT · Entity 5502	GrantStock Option (right to buy) · Derivative	11,538	$0.00 Strike: $15.63	$0.00	Disclosure SEC source: 0001179110-17-009253 · edgar.xml · derivative · entry 1 Borisy Alexis · CIK 0001319446 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,538 Underlying: Common Stock · 11,538 shares Expires 2027-06-14 F1 · derivative.exercise_date: This option granted on June 15, 2017 and is scheduled to vest in full on June 15, 2018. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.